|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.08 USD | +0.07% |
|
+0.22% | -17.20% |
| Apr. 24 | HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69 | MT |
| Apr. 23 | Argus Cuts Price Target on Gilead Sciences to $75 From $85 | MT |
Gilead Subsidiary to Launch Authorized Generics to Treat HCV
Attachments
Disclaimer
Gilead Sciences Inc. published this content on 24 September 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 24 September 2018 13:18:05 UTC
| 1st Jan change | Capi. | |
|---|---|---|
| -17.20% | 83.65B | |
| +25.61% | 660B | |
| +25.87% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +7.09% | 219B | |
| -9.12% | 196B | |
| +5.01% | 199B | |
| -8.75% | 149B |
GILEAD SCIENCES, INC. 
